Rawan Faramand, MD

Cancer Focus:
Leukemia, MDS, Myelodysplastic Syndromes (MDS)

   Dr. Faramand earned her MD from Virginia Commonwealth University School of Medicine in Richmond. She completed an Internal Medicine Residency at the University of Maryland Medical Center, where she also served as Chief Resident. She recently completed a Hematology and Medical Oncology Fellowship at the University of South Florida Morsani College of Medicine and Moffitt Cancer Center, where she also served as Chief Fellow.    Dr. Faramand’s clinical focus is on allogeneic stem cell transplantation for hematologic malignancies. She is particularly interested in improving outcomes for patients with acute leukemias, including acute lymphoblastic leukemias and acute myeloid leukemia as well as myelodysplastic syndrome. Dr. Faramand’s research is primarily focused on improving outcomes for patients with leukemia, and she has worked on specific projects during her fellowship under the mentorship of Drs. Mishra, Davila and Chavez. 

Education & Training

Board Certification:

• Hematology - Oncology
• Medical Oncology - Medical Oncology

Fellowship:

• University of South Florida - Hematology & Medical Oncology

Residency:

• Maryland Medical Center - Internal Medicine

Medical School:

• Virginia Commonwealth University - MD

• Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: 38194367. Pmcid: PMC10905320.
• Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, Khimani F, Lazar-Yan A, Ochoa-Bayona JL, Liu H, Jain MD, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations. Am J Hematol. 2024 Mar. Pubmedid: 38546371.
• Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: 37952648.
• Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Feb. Pubmedid: 38429222.
• Gonzalez R, Gaskill E, Padilla M, Pidala J, Lazaryan A, Perez L, Khimani F, Faramand R. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2023 Sep.29(9):577.e1-577.e9. Pubmedid: 37355201.
• Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep.9(38):eadg3919. Pubmedid: 37738350. Pmcid: PMC10516499.
• Keit E, Liveringhouse C, Figura N, Weygand J, Sandoval ML, Garcia G, Peters J, Nieder M, Faramand R, Khimani F, Kim S, Robinson TJ, Johnstone PAS, Penagaricano J, Latifi K. Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation. Technol Cancer Res Treat. 2023 Jan.22. Pubmedid: 37287260. Pmcid: PMC10272663.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr.9(1):18. Pubmedid: 37005652. Pmcid: PMC10067156.
• Mittal K, Sheen M, Wheelden M, Faramand R, Teplinsky E, Joshi M. Dobbs v Jackson- Rewriting Women's Autonomy in Cancer Care. JCO Oncol Pract. 2023 Apr.19(4):157-159. Pubmedid: 36652658.
• Ghobadi A, Slade M, Kantarjian HM, Alvarenga J, Aldoss I, Mohammed K, Jabbour EJ, Faramand RG, Shah BD, Locke FL, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 Nov.140(20):2101-2112. Pubmedid: 35877996.
• Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
• Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, Franke N, Locke FL, Jain MD, Wong D, Kuruvilla JG. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem. 2022 Feb.3(1):223-227. Pubmedid: 35846190. Pmcid: PMC9175700.
• Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: 36174934. Pmcid: PMC9791940.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022 Aug.140(5):491-503. Pubmedid: 35476848. Pmcid: PMC9353150.
• Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: 35017119.
• Hansen DK, Dam M, Faramand RG. Toxicities associated with adoptive cellular therapies. Best Pract Res Clin Haematol. 2021 Sep.34(3):101287. Pubmedid: 34625233.
• Mushtaq S, Prabakaran S, Elharake M, Mirza S, Ravindran A, Faramand R, Sokol L. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. ACG Case Rep J. 2021 Nov.8(11):e00698. Pubmedid: 34820467. Pmcid: PMC8608261.
• Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
• Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
• Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
• Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
• Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
• Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
• Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
• Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: 33658647.
• Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest. 2021 Jan.131(2). Pubmedid: 33463538. Pmcid: PMC7810492.
• Faramand RG, Davila ML. CAR T-cell hematotoxicity: is inflammation the key?. Blood. 2021 Dec.138(24):2447-2448. Pubmedid: 34914831.
• Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
• Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
• Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan.126(2):293-303. Pubmedid: 31568564.
• Mishra A, Bigam KD, Extermann M, Faramand R, Thomas K, Pidala JA, Baracos VE. Sarcopenia and low muscle radiodensity associate with impaired FEV1 in allogeneic haematopoietic stem cell transplant recipients. J Cachexia Sarcopenia Muscle. 2020 Dec.11(6):1570-1579. Pubmedid: 32729255. Pmcid: PMC7749567.
• Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Brit J Haematol. 2020 Apr.189(2):313-317. Pubmedid: 31804715.
• Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019 Feb.60(2):309-316. Pubmedid: 29963932.
• Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A. Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms. Appl Immunohistochem Mol Morphol. 2017 May.25(5):334-337. Pubmedid: 26945443.
• Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015 May.90(5):E77-E79. Pubmedid: 25651001.
• Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Semin Hematol. 2015 Jul.52(3):165-171. Pubmedid: 26111463.

Title: Study to develop a predictive model of immune-related adverse events in patients treated with axicabtagene ciloleucel
Sponsor: Kite Pharma
PI: Faramand, R.